AWAKN LIFE SCIENCES CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.17 CAD | +6.25% |
|
-22.73% | +17.24% |
| Sales 2022 | 0.24 0.32 19.68 | Sales 2023 | 1.5 2.05 124.65 | Capitalization | 10.88M 14.89M 907M |
|---|---|---|---|---|---|
| Net income 2022 | -15M -20.52M -1.25B | Net income 2023 | -9M -12.31M -750M | EV / Sales 2022 | 21,58,80,506 x |
| Net Debt 2022 | 186K 254K 15.48M | Net Debt 2023 | 1.74M 2.39M 145M | EV / Sales 2023 | 84,42,474 x |
| P/E ratio 2022 |
-2.81
x | P/E ratio 2023 |
-0.92
x | Employees | 44 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 91.55% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +6.25% | ||
| 1 week | -22.73% | ||
| Current month | -2.86% | ||
| 1 month | +41.67% | ||
| 3 months | +21.43% | ||
| 6 months | -10.53% | ||
| Current year | +17.24% |
1 week
0.15
0.21
1 month
0.120.23
Current year
0.100.23
1 year
0.060.38
3 years
0.063.35
5 years
0.063.35
10 years
0.063.35
| Managers | Title | Age | Since |
|---|---|---|---|
Anthony Tennyson
FOU | Founder | - | 01/20/01 |
Jonathan Held
FOU | Founder | 38 | 01/20/01 |
Shaun McNulty
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Paul Carter
BRD | Director/Board Member | 63 | 14/21/14 |
Stephen Page
BRD | Director/Board Member | - | - |
George Scorsis
FOU | Founder | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/24/03 | 0.17 | +6.25% | 12 856 |
| 02/24/02 | 0.16 | -8.57% | 3,000 |
| 01/24/01 | 0.175 | 0.00% | 16,390 |
| 30/24/30 | 0.175 | 0.00% | 2,004 |
| 29/24/29 | 0.175 | -20.45% | 5,255 |
Delayed Quote Canadian Securities Exchange, May 03, 2024 at 11:16 pm IST
More quotes
Awakn Life Sciences Corp. is a Canada-based biotechnology company. The Company is engaged in the research, development, and commercializing of therapeutics to treat addiction with a focus on Alcohol Use Disorder (AUD). The Company's therapeutics are focused on the brain circuits that drive addiction, multiple receptors rather than the traditional single drug receptor targets. The Company operates through three segments: development, delivery and corporate. The development segment, which focuses on researching and developing psychedelic drugs and therapies, ketamine-assisted psychotherapy and methylenedioxy-methamphetamine (MDMA)-assisted psychotherapy to treat substance and behavioral addictions. The delivery segment, which includes a chain of medical psychedelic clinics across Europe. The Company operates in the United Kingdom (UK), Ireland and Canada.
Calendar
12/06/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +17.24% | 4.61M | |
| +25.69% | 48.09B | |
| +46.90% | 40.62B | |
| -3.46% | 40.43B | |
| -6.20% | 28.36B | |
| +9.17% | 24.89B | |
| -20.42% | 19.01B | |
| +28.07% | 12.09B | |
| +0.17% | 11.88B | |
| -1.24% | 11.8B |
- Stock Market
- Equities
- AWKN Stock
